Poster Session E - Tuesday Afternoon
Adegboyega O. Olayode, MD, MPH
Emory University School of Medicine
Atlanta, GA
Insured (n= 171,199) | Uninsured (n= 7,442) | p-value | |
Tumor size, mean (standard deviation), cm | 4.42 +/- 4.6 | 5.50 +/- 4.7 | < 0.001 |
Differentiation grade, No. (%) | < 0.001 | ||
Well differentiated | 12,244 (7.15) | 384 (5.16) | |
Moderately differentiated | 36,394 (21.26) | 1,230 (16.53) | |
Poorly differentiated | 78,541 (45.88) | 3,960 (53.21) | |
Undifferentiated, anaplastic | 3,076 (1.80) | 114 (1.53) | |
Cell type not determined | 40,944 (23.92) | 1,754 (23.57) | |
Tumor Stage at diagnosis, No. (%) | < 0.001 | ||
Stage 0 | 3,081 (1.80) | 40 (0.54) | |
Stage I | 35,769 (20.89) | 852 (11.45) | |
Stage II | 21,970 (12.83) | 723 (9.72) | |
Stage III | 27,921 (16.31) | 1,159 (15.57) | |
Stage IV | 51,726 (30.21) | 3,436 (46.17) | |
Not applicable | 5,066 (2.96) | 205 (2.75) | |
Unknown | 25,666 (14.99) | 1,027 (13.80) | |
Metastatic disease, No. (%) | < 0.001 | ||
No | 115,122 (70.82) | 3,815 (55.10) | |
Yes | 42,370 (26.07) | 2,906 (41.97) | |
Not Applicable | 5,058 (3.11) | 203 (2.93) |